(asset development)
From scientific discovery to global pharmaceutical asset.
At Aether, research and development are oriented toward building value.
As a Pharmaceutical Asset Venture Builder, we identify and develop scientific discoveries with the potential to become protected, technically validated pharmaceutical assets, strategically positioned for licensing, industrial partnership, or other monetization transactions.
Each asset advances through a structured journey of scientific and technological de-risking, TRL maturation, intellectual property strategy, and specialized governance.
A scientific discovery is not yet a pharmaceutical asset.
(the approach)
Turning science into a pharmaceutical asset takes more than generating experimental results. It requires identifying application potential, building intellectual protection, reducing critical uncertainties, and generating the evidence needed to progressively increase the asset's maturity and value.
At the Aether platform, development follows an asset-building logic: every scientific, technological, and strategic decision should help make the asset more robust, protectable, and attractive to future industrial partners, licensees, and specialized life sciences investors.
Scientific and technological execution is carried out in coordination with ICT AetherBio+, universities, research centers, specialists, and technology partners, within a governance structure defined for each asset.
Four dimensions.
One integrated approach.
01 / 04
Scientific and Technological De-risking
We identify each asset's critical uncertainties and structure its development to progressively reduce them. Scientific evidence generation, technological validation, and maturity advancement are guided by decision milestones, allowing capital and resources to be concentrated on assets that show greater consistency and value potential. The goal isn't just to advance the research - it's to increase the asset's quality and reliability.
Intellectual Property and Defensibility
Intellectual property is a central part of building the pharmaceutical asset. We assess ownership, novelty, protection potential, freedom to operate, and the strategy for expanding protection throughout development. Protected science stops being merely knowledge and becomes an intangible asset with the potential to generate economic value.
Specialized Scientific Governance
Each asset is accompanied by specialists selected according to its scientific, technological, and therapeutic nature. Scientific governance strengthens the quality of decisions, methodological rigor, and independent review of development milestones, supporting decisions to continue, redirect, or say NO GO. At Aether, moving forward also means knowing when not to.
Asset Maturation and Value Creation
Development is structured to progressively increase each asset's scientific, technological, and strategic maturity. As relevant risks are reduced, evidence is consolidated, and intellectual property is strengthened, the asset broadens its appeal to the pharmaceutical industry and specialized partners. Each advance should increase not just the TRL, but also the asset's strategic quality and monetization potential.
Four dimensions. One integrated approach.
Scientific and Technological De-risking
We identify each asset's critical uncertainties and structure its development to progressively reduce them. Scientific evidence generation, technological validation, and maturity advancement are guided by decision milestones, allowing capital and resources to be concentrated on assets that show greater consistency and value potential. The goal isn't just to advance the research - it's to increase the asset's quality and reliability.
Intellectual Property and Defensibility
Intellectual property is a central part of building the pharmaceutical asset. We assess ownership, novelty, protection potential, freedom to operate, and the strategy for expanding protection throughout development. Protected science stops being merely knowledge and becomes an intangible asset with the potential to generate economic value.
Specialized Scientific Governance
Each asset is accompanied by specialists selected according to its scientific, technological, and therapeutic nature. Scientific governance strengthens the quality of decisions, methodological rigor, and independent review of development milestones, supporting decisions to continue, redirect, or say NO GO. At Aether, moving forward also means knowing when not to.
Asset Maturation and Value Creation
Development is structured to progressively increase each asset's scientific, technological, and strategic maturity. As relevant risks are reduced, evidence is consolidated, and intellectual property is strengthened, the asset broadens its appeal to the pharmaceutical industry and specialized partners. Each advance should increase not just the TRL, but also the asset's strategic quality and monetization potential.
(asset profile)
What we aim to build.
Aether identifies and selects scientific discoveries and health technologies with the potential to become protected, developable, and licensable pharmaceutical assets. We prioritize opportunities that show a consistent combination of the following attributes:
Robust scientific grounding
Hypotheses backed by experimental evidence, technically consistent methodology, and data that allow critical analysis, validation, and the definition of the next development milestones.
Translational potential
A concrete possibility of transforming the scientific discovery into a therapeutic solution or technology applicable to pharmaceutical development.
Intellectual property potential
The ability to build or strengthen an intellectual property position that contributes to the asset's exclusivity, defensibility, and strategic value.
Development and monetization potential
A technically viable development pathway and a clear hypothesis for generating value through licensing, strategic partnership, technology transfer, or another transaction related to the asset.
Opportunities can originate at universities, science and technology institutions, research centers, scientific startups, independent researchers, and other innovation organizations, in Brazil or abroad.
(our development platform)
A platform to build and mature pharmaceutical assets.
Pipeline
Explore the assets that make up Aether's pipeline, organized by maturity stage, therapeutic area, and development status.
Development journey
Track how assets progress through technology readiness levels and the key milestones associated with risk reduction and value creation.
Science and technology integrated into asset building.
ICT AetherBio+ is part of the Aether platform as an institutional environment for science, technology, and innovation, supporting the execution and governance of the assets' scientific and technological development. Working with universities, research centers, specialists, and technology partners, the ICT contributes to generating evidence, advancing technology readiness, and executing the development programs defined for each asset. This architecture makes it possible to connect science, intellectual property, capital, and development strategy into a single value-building thesis.